Mumbai: Actor Irrfan Khan today revealed that he has been diagnosed with a neuroendocrine tumour and is out of the country for treatment.
The actor, 51, said it has been difficult dealing with the disease but people around him have given him hope and support to fight it.
“The unexpected makes us grow, which is what the past few days have been about. Learning that I have been diagnosed with NeuroEndocrine Tumour as of now has admittedly been difficult, but the love and strength of those around me and that I found within me has brought me to a place of hope,” Irrfan said in a statement.
“The journey of this is taking me out of the country, and I request everyone to continue sending their wishes,” he added.
The actor, who has essayed memorable roles in several realistic films, also addressed the rumours surrounding his illness, saying neuro is not always about the brain but thanked those who did not speculate about his health.
Neuroendocrine tumours (NETs) are neoplasms that arise from cells of the endocrine (hormonal) and nervous systems. Many are benign, while some are malignant. They most commonly occur in the intestine, where they are often called carcinoid tumours, but they are also found in the pancreas, lung and the rest of the body.
Although there are many kinds of NETs, they are treated as a group of tissue because the cells of these neoplasms share common features, such as looking similar, having special secretory granules, and often producing biogenic amines and polypeptide hormones.
The World Health Organization (WHO) classification scheme places neuroendocrine tumours into three main categories, which emphasize the tumour grade rather than the anatomical origin:
- well-differentiated neuroendocrine tumours, further subdivided into tumours with benign and those with uncertain behaviour
- well-differentiated (low grade) neuroendocrine carcinomas with low-grade malignant behaviour
- poorly differentiated (high grade) neuroendocrine carcinomas, which are the large cell neuroendocrine and small cell carcinomas
- Additionally, the WHO scheme recognizes mixed tumours with both neuroendocrine and epithelial carcinoma features, such as goblet cell cancer, a rare gastrointestinal tract tumour
Placing a given tumour into one of the categories depends on well-defined histological features: size, lymphovascular invasion, mitotic counts, Ki-67 labelling index, invasion of adjacent organs, the presence of metastases and whether they produce hormones.